Drug Patents Expiring in 2029

1. Drug name - ABILIFY MYCITE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9258035 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same Mar, 2029

(6 years from now)

US9060708 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same Mar, 2029

(6 years from now)

US8674825 OTSUKA Pharma-informatics system Apr, 2029

(6 years from now)

US8956288 OTSUKA In-body power source having high surface area electrode Jul, 2029

(6 years from now)

US10441194 OTSUKA Ingestible event marker systems Jul, 2029

(6 years from now)

US8945005 OTSUKA Controlled activation ingestible identifier Aug, 2029

(6 years from now)

US9433371 OTSUKA In-body device with virtual dipole signal amplification Sep, 2029

(6 years from now)

US8718193 OTSUKA Active signal processing personal health signal receivers Dec, 2029

(7 years from now)

US9149577 OTSUKA Body-associated receiver and method Dec, 2029

(7 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Method of using a receiver to receive a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

2. Drug name - ACANYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504704 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US10220049 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US8895070 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US10624918 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US9561208 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US9078870 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US10137142 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US8663699 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US8288434 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Aug, 2029

(6 years from now)

Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient

Treatment: Treatment of acne vulgaris; topical treatment of acne vulgaris; topical treatment of acne vulgaris in patients 12 years or older; treatment of acne; Topical treatment of acne vulgaris in patients 12 years or older; Treatment of acne; Topical treatment of acne vulgaris; treatment of acne; treatment of acne vulgaris; topical treatment of acne vulgaris; treatment of acne vulgaris; topical treatment of acne vulgaris in patients 12 years or older

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
2.5%;EQ 1.2% BASE GEL;TOPICAL Prescription
3.75%;EQ 1.2% BASE GEL;TOPICAL Prescription

3. Drug name - ACTOPLUS MET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9320714 TAKEDA PHARMS USA Tablet Feb, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
500MG;EQ 15MG BASE TABLET;ORAL Prescription
850MG;EQ 15MG BASE TABLET;ORAL Prescription

4. Drug name - ACUVAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7842714 ALLERGAN Ketorolac tromethamine compositions for treating ocular pain
Aug, 2029

(6 years from now)

CN103976943B ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

CN103976943A ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

IN201006461P1 ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

IN286644B ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

EP2257275B1 ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

EP2446878A1 ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

EP2257275A2 ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

EP2446878B1 ALLERGAN Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain
Mar, 2029

(6 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.45% SOLUTION/DROPS;OPHTHALMIC Prescription

5. Drug name - ALIQOPA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46856 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Oct, 2029

(7 years from now)

More Information on Dosage
Strength Dosage Availability
60MG/VIAL POWDER;INTRAVENOUS Prescription

6. Drug name - ALUNBRIG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9273077 TAKEDA PHARMS USA Phosphorus derivatives as kinase inhibitors May, 2029

(6 years from now)

Drugs and Companies using BRIGATINIB ingredient

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET;ORAL Prescription
90MG TABLET;ORAL Prescription
180MG TABLET;ORAL Prescription

7. Drug name - ANGIOMAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7582727

(Pediatric)

SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same Jan, 2029

(6 years from now)

US7598343

(Pediatric)

SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same Jan, 2029

(6 years from now)

Drugs and Companies using BIVALIRUDIN ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
250MG/VIAL INJECTABLE;INTRAVENOUS Prescription

8. Drug name - ARNUITY ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8201556 GLAXOSMITHKLINE Medicament dispenser Feb, 2029

(6 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
0.05MG/INH POWDER;INHALATION Prescription
0.1MG/INH POWDER;INHALATION Prescription
0.2MG/INH POWDER;INHALATION Prescription

9. Drug name - ATRIPLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8598185 GILEAD SCIENCES Unitary pharmaceutical dosage form Apr, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
600MG;200MG;300MG TABLET;ORAL Prescription

10. Drug name - AUVI-Q

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8226610 KALEO INC Medical injector with compliance tracking and monitoring Apr, 2029

(6 years from now)

US8021344 KALEO INC Medicament delivery device configured to produce an audible output Nov, 2029

(7 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription
EQ 0.15MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription
EQ 0.3MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription

11. Drug name - BAXDELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8871938 MELINTA Process for making quinolone compounds
Sep, 2029

(6 years from now)

USRE46617 MELINTA Process for making quinolone compounds
Dec, 2029

(7 years from now)

CN102164912A MELINTA Process For Preparing Quinolone Compounds
Sep, 2029

(6 years from now)

CN102164912B MELINTA Preparing Process Of Quinolones Compound
Sep, 2029

(6 years from now)

IN201101315P2 MELINTA Process For Making Quinolone Compounds
Sep, 2029

(6 years from now)

IN290385B MELINTA Process For Making Quinolone Compounds
Sep, 2029

(6 years from now)

EP2346855A4 MELINTA Process For Making Quinolone Compounds
Sep, 2029

(6 years from now)

EP2346855B1 MELINTA Process For Making Quinolone Compounds
Sep, 2029

(6 years from now)

EP2346855A2 MELINTA Process For Making Quinolone Compounds
Sep, 2029

(6 years from now)

EP3214083B1 MELINTA Process For Making Quinolone Compounds
Sep, 2029

(6 years from now)

EP3214083A1 MELINTA Process For Making Quinolone Compounds
Sep, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750822 MELINTA Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US8410077 MELINTA Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US9200088 MELINTA Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US7635773 MELINTA Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 300MG BASE/VIAL POWDER;INTRAVENOUS Prescription

12. Drug name - BELSOMRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7951797 MERCK SHARP DOHME Substituted diazepan orexin receptor antagonists
Nov, 2029

(7 years from now)

Drugs and Companies using SUVOREXANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

13. Drug name - BESIVANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8937062 BAUSCH AND LOMB Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria Nov, 2029

(7 years from now)

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

Treatment: Method of treating ocular bacterial infections

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.6% BASE SUSPENSION/DROPS;OPHTHALMIC Prescription

14. Drug name - BRAFTOVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8946250 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Jul, 2029

(6 years from now)

CN102105459B ARRAY BIOPHARMA INC 3,4-Diarylpyrazoles As Protein Kinase Inhibitors
Jul, 2029

(6 years from now)

CN102105459A ARRAY BIOPHARMA INC 3,4-Diarylpyrazoles As Protein Kinase Inhibitors
Jul, 2029

(6 years from now)

EP2324008A1 ARRAY BIOPHARMA INC 3,4-Diarylpyrazoles As Protein Kinase Inhibitors
Jul, 2029

(6 years from now)

EP2324008B1 ARRAY BIOPHARMA INC 3,4-Diarylpyrazoles As Protein Kinase Inhibitors
Jul, 2029

(6 years from now)

Drugs and Companies using ENCORAFENIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG CAPSULE;ORAL Discontinued
75MG CAPSULE;ORAL Prescription

15. Drug name - BREO ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11116721 GLAXO GRP LTD Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol Feb, 2029

(6 years from now)

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Treatment: Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations; indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
0.1MG/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription
0.2MG/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

16. Drug name - BRISDELLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8658663 SEBELA IRELAND LTD Method of treating thermoregulatory disfunction with paroxetine
Apr, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 7.5MG BASE CAPSULE;ORAL Prescription

17. Drug name - BROMSITE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778999 SUN PHARM Non-steroidal anti-inflammatory ophthalmic compositions Aug, 2029

(6 years from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Treatment: Treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.075% ACID SOLUTION/DROPS;OPHTHALMIC Prescription

18. Drug name - BYDUREON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8827963 ASTRAZENECA AB Administering device with holding mechanism Feb, 2029

(6 years from now)

US8690837 ASTRAZENECA AB Mixing device for a two-chamber ampoule May, 2029

(6 years from now)

US8827963

(Pediatric)

ASTRAZENECA AB Administering device with holding mechanism Aug, 2029

(6 years from now)

US8690837

(Pediatric)

ASTRAZENECA AB Mixing device for a two-chamber ampoule Nov, 2029

(7 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued
2MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued

19. Drug name - CALDOLOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138404 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen Sep, 2029

(6 years from now)

US9295639 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen Sep, 2029

(6 years from now)

US8871810 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen Sep, 2029

(6 years from now)

US9649284 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen Sep, 2029

(6 years from now)

US8735452 CUMBERLAND PHARMS Treating patients with intravenous ibuprofen Sep, 2029

(6 years from now)

US9114068 CUMBERLAND PHARMS Treating patients with intravenous ibuprofen Sep, 2029

(6 years from now)

Drugs and Companies using IBUPROFEN ingredient

Treatment: Methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof; Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity; Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treating pain, inflammation and/or fever with intravenous ibuprofen such that mean arterial blood pressure does not increase the dosage interval

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
400MG/4ML (100MG/ML) SOLUTION;INTRAVENOUS Discontinued
800MG/8ML (100MG/ML) SOLUTION;INTRAVENOUS Prescription
800MG/200ML (4MG/ML) SOLUTION;INTRAVENOUS Prescription

20. Drug name - CAPLYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE48825 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
Mar, 2029

(6 years from now)

US9586960 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
Mar, 2029

(6 years from now)

US8648077 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
Dec, 2029

(7 years from now)

CN102046175A INTRA-CELLULAR Substituted Heterocycle Fused Gamma-Carbolines Solid
Mar, 2029

(6 years from now)

CN102046175B INTRA-CELLULAR A Heterocyclic Ring Fused Gamma-Carbolines Solid
Mar, 2029

(6 years from now)

EP2262505B1 INTRA-CELLULAR Substituted Heterocycle Fused Gamma-Carbolines Solid
Mar, 2029

(6 years from now)

EP2262505A2 INTRA-CELLULAR Substituted Heterocycle Fused Gamma-Carbolines Solid
Mar, 2029

(6 years from now)

EP2262505A4 INTRA-CELLULAR Substituted Heterocycle Fused Gamma-Carbolines Solid
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9199995 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals Mar, 2029

(6 years from now)

US10117867 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders May, 2029

(6 years from now)

US9616061 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders May, 2029

(6 years from now)

USRE48839 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders Dec, 2029

(7 years from now)

US8598119 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders Dec, 2029

(7 years from now)

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

Treatment: Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia; Treatment of bipolar depression; Treatment of bipolar depression; treatment of schizophrenia; Treatment of schizophrenia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 42MG BASE CAPSULE;ORAL Prescription

21. Drug name - CARNEXIV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7635773 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US8410077 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US9750822 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

Drugs and Companies using CARBAMAZEPINE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
200MG/20ML (10MG/ML) SOLUTION;INTRAVENOUS Discontinued

22. Drug name - COLCRYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7601758 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares Feb, 2029

(6 years from now)

US8440721 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent Feb, 2029

(6 years from now)

US8440722 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent Feb, 2029

(6 years from now)

US7906519 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent Feb, 2029

(6 years from now)

US7820681 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent Feb, 2029

(6 years from now)

US7915269 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent Feb, 2029

(6 years from now)

Drugs and Companies using COLCHICINE ingredient

Treatment: Method of treating gout flares; Method of using colchicine for the prophylaxis of gout flares; Method of administering colchicine to familial mediterranean fever patients

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.6MG TABLET;ORAL Prescription

23. Drug name - CONSENSI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662315 PURPLE BIOTECH Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs May, 2029

(6 years from now)

Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient

Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE;200MG TABLET;ORAL Discontinued
EQ 5MG BASE;200MG TABLET;ORAL Discontinued
EQ 10MG BASE;200MG TABLET;ORAL Discontinued

24. Drug name - CONTRAVE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8088786 NALPROPION Layered pharmaceutical formulations Feb, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
90MG;8MG TABLET, EXTENDED RELEASE;ORAL Prescription

25. Drug name - COPIKTRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216982 SECURA Certain chemical entities, compositions and methods Jan, 2029

(6 years from now)

Drugs and Companies using DUVELISIB ingredient

Treatment: For the treatment of patients with follicular lymphoma (fl); for the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG CAPSULE;ORAL Prescription
25MG CAPSULE;ORAL Prescription

26. Drug name - COTELLIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7803839 GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Nov, 2029

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription

27. Drug name - DAKLINZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8329159 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Jul, 2029

(6 years from now)

EP2049522A2 BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2029

(6 years from now)

EP2049522B1 BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 30MG BASE TABLET;ORAL Discontinued
EQ 60MG BASE TABLET;ORAL Discontinued
EQ 90MG BASE TABLET;ORAL Discontinued

28. Drug name - DESYREL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8133893 PRAGMA Trazodone and trazodone hydrochloride in purified form
Mar, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Discontinued
100MG TABLET;ORAL Discontinued
150MG TABLET;ORAL Discontinued
300MG TABLET;ORAL Discontinued

29. Drug name - DEXILANT SOLUTAB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241910 TAKEDA PHARMS USA Orally-disintegrating solid preparation Mar, 2029

(6 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL Discontinued

30. Drug name - DOVATO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(7 years from now)

CN102245182B VIIV HLTHCARE Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediates For Synthesis
Dec, 2029

(7 years from now)

CN102245182A VIIV HLTHCARE Synthesis Of Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediate
Dec, 2029

(7 years from now)

IN373756B VIIV HLTHCARE Process For The Preparation Of Carbamoylpyrid One Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

IN201838011858A VIIV HLTHCARE Process For The Preparation Of Carbamoylpyridone Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

EP2376080A4 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080B1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080A1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE;300MG TABLET;ORAL Prescription

31. Drug name - DUAKLIR PRESSAIR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000517 ASTRAZENECA Dosage and formulation Mar, 2029

(6 years from now)

US10085974 ASTRAZENECA Dosage and formulation Mar, 2029

(6 years from now)

Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)

Dosage: POWDER, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.4MG/INH;0.012MG/INH POWDER, METERED;INHALATION Prescription

32. Drug name - DURYSTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7799336 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods Apr, 2029

(6 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: NA

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
10MCG IMPLANT;OPHTHALMIC Prescription

33. Drug name - DUTREBIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7754731 MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7754731

(Pediatric)

MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor Sep, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;EQ 300MG BASE TABLET;ORAL Discontinued

34. Drug name - DUZALLO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8546437 IRONWOOD PHARMS INC Compounds and compositions and methods of use Apr, 2029

(6 years from now)

US8084483 IRONWOOD PHARMS INC Compounds and compositions and methods of use Aug, 2029

(6 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG;200MG TABLET;ORAL Discontinued
300MG;200MG TABLET;ORAL Discontinued

35. Drug name - DYANAVEL XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes Mar, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
2MG/ML;EQ 0.5MG BASE/ML SUSPENSION, EXTENDED RELEASE;ORAL Prescription

36. Drug name - ELLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735380 LAB HRA PHARMA Ulipristal acetate tablets Feb, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
30MG TABLET;ORAL Prescription

37. Drug name - EMBEDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623418 ALPHARMA PHARMS Pharmaceutical composition Nov, 2029

(7 years from now)

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: Treatment of moderate to severe chronic pain by administering an intact composition as claimed

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG;0.8MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
30MG;1.2MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
50MG;2MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
60MG;2.4MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
80MG;3.2MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
100MG;4MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued

38. Drug name - EPCLUSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(6 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus Mar, 2029

(6 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2029

(6 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Sep, 2029

(6 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus Sep, 2029

(6 years from now)

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG;50MG TABLET;ORAL Prescription
400MG;100MG TABLET;ORAL Prescription

39. Drug name - ESBRIET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7635707 GENENTECH INC Pirfenidone treatment for patients with atypical liver function Apr, 2029

(6 years from now)

US8609701 GENENTECH INC Pirfenidone treatment for patients with atypical liver function Apr, 2029

(6 years from now)

US8592462 GENENTECH INC Pirfenidone treatment for patients with atypical liver function Apr, 2029

(6 years from now)

US7566729 GENENTECH INC Modifying pirfenidone treatment for patients with atypical liver function Apr, 2029

(6 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Treatment: Continued dosing or dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis; Continued dosing or dosage modification following elvated liver enzymes in use of pirfenidone; Dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, then at least 1600mg/day in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, followed by administering at least 1600 mg/day in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by administering sub-1600 mg/day, following by administering at least 1600 mg/day in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by administering sub-2400mg/day dose, followed by administering 2403mg/day in treatment of ipf; dosing 2403 mg/day pirfenidone following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-1600 mg/day dose, followed by administering at least 1600 mg/day dose in treatment of ipf; dosing of at least 1600 mg/day following grade 2 liver abnormality in biomarker ast and/or alt after pirfenidone administration in treatment of ipf; dosing of at least 1600 mg/day following grade 2 abnormality in liver function biomarker after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, followed by full daily dose in treatment of ipf; Dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within limits, then sub-2400mg/day dose, then full daily dose in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-2400mg/day dose then full daily dose in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-2400 mg/day dose then full day daily dose in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, then sub-2400mg/day dose, then full daily dose in treatment of ipf

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
267MG TABLET;ORAL Prescription
534MG TABLET;ORAL Discontinued
801MG TABLET;ORAL Prescription

40. Drug name - EUCRISA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8039451 ANACOR PHARMS INC Boron-containing small molecules
Jun, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8039451

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules Dec, 2029

(7 years from now)

Drugs and Companies using CRISABOROLE ingredient

Treatment: NA

Dosage: OINTMENT;TOPICAL

More Information on Dosage
Strength Dosage Availability
2% OINTMENT;TOPICAL Prescription

41. Drug name - EVOMELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077 ACROTECH Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US9200088 ACROTECH Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE/VIAL POWDER;INTRAVENOUS Prescription

42. Drug name - EVOTAZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148374 BRISTOL-MYERS SQUIBB Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 300MG BASE;150MG TABLET;ORAL Prescription

43. Drug name - EVZIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8226610 KALEO INC Medical injector with compliance tracking and monitoring Apr, 2029

(6 years from now)

US8021344 KALEO INC Medicament delivery device configured to produce an audible output Nov, 2029

(7 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/0.4ML (0.4MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

44. Drug name - EVZIO (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8226610 KALEO INC Medical injector with compliance tracking and monitoring Apr, 2029

(6 years from now)

US8021344 KALEO INC Medicament delivery device configured to produce an audible output Nov, 2029

(7 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.4ML (2MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

45. Drug name - EXONDYS 51

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47769 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof Feb, 2029

(6 years from now)

Drugs and Companies using ETEPLIRSEN ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/2ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription
500MG/10ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription

46. Drug name - FARXIGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(7 years from now)

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

47. Drug name - FERRIPROX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703156 CHIESI Liquid formulation for deferiprone with palatable taste Oct, 2029

(7 years from now)

Drugs and Companies using DEFERIPRONE ingredient

Treatment: Method of treating transfusional iron overload

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
80MG/ML SOLUTION;ORAL Discontinued
100MG/ML SOLUTION;ORAL Prescription

48. Drug name - FINACEA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9211259 LEO PHARMA AS Antibiotic kit and composition and uses thereof Feb, 2029

(6 years from now)

Drugs and Companies using AZELAIC ACID ingredient

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
15% AEROSOL, FOAM;TOPICAL Prescription

49. Drug name - FIRMAGON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729739 FERRING Methods of treating prostate cancer with GnRH antagonist Feb, 2029

(6 years from now)

US10973870 FERRING Methods of treating prostate cancer with GnRH antagonist Feb, 2029

(6 years from now)

US9579359 FERRING Method of treating prostate cancer with GnRH antagonist Feb, 2029

(6 years from now)

Drugs and Companies using DEGARELIX ACETATE ingredient

Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 80MG BASE/VIAL POWDER;SUBCUTANEOUS Prescription
EQ 120MG BASE/VIAL POWDER;SUBCUTANEOUS Prescription

50. Drug name - FYARRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8911786 AADI Nanoparticle comprising rapamycin and albumin as anticancer agent Feb, 2029

(6 years from now)

Drugs and Companies using SIROLIMUS ingredient

Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma)

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription

51. Drug name - GALAFOLD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8592362 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases Feb, 2029

(6 years from now)

US10813921 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases Feb, 2029

(6 years from now)

USRE48608 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases Feb, 2029

(6 years from now)

US9095584 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases Feb, 2029

(6 years from now)

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 123MG BASE CAPSULE;ORAL Prescription

52. Drug name - GELNIQUE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259388 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions Nov, 2029

(7 years from now)

US10449173 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions Nov, 2029

(7 years from now)

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Treatment: Treatment of overactive bladder by application of oxybutynin chloride gel to skin; Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel

Dosage: GEL;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
10% (100MG/PACKET) GEL;TRANSDERMAL Prescription

53. Drug name - GEMTESA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8653260 UROVANT Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
Apr, 2029

(6 years from now)

CN102056917A UROVANT Hydroxymethyl Pyrrolidines As [Beta]3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

CN102391255B UROVANT Hydroxymethyl Pyrrolidine As 3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

CN102391255A UROVANT Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonist
Apr, 2029

(6 years from now)

CN102056917B UROVANT Hydroxymethyl Pyrrolidine As 3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

EP2276756B1 UROVANT Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

EP2276756A1 UROVANT Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

EP2276756B8 UROVANT Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

EP2276756B9 UROVANT Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

Drugs and Companies using VIBEGRON ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
75MG TABLET;ORAL Prescription

54. Drug name - GENOSYL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9701538 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) Jan, 2029

(6 years from now)

US8944049 VERO BIOTECH Systems and devices for generating nitric oxide Aug, 2029

(6 years from now)

US9604028 VERO BIOTECH Systems and devices for generating nitric oxide Aug, 2029

(6 years from now)

US10926054 VERO BIOTECH Systems and devices for generating nitric oxide Aug, 2029

(6 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: A method for delivering nitric oxide to a patient with pulmonary hypertension or hypoxia

Dosage: GAS;INHALATION

More Information on Dosage
Strength Dosage Availability
800PPM GAS;INHALATION Prescription

55. Drug name - GENVOYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148374 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9891239 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics Sep, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;150MG;200MG;EQ 10MG BASE TABLET;ORAL Prescription

56. Drug name - GIAPREZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9867863 LA JOLLA PHARMA Method of treating low blood pressure Dec, 2029

(7 years from now)

US10335451 LA JOLLA PHARMA Method of treating low blood pressure Dec, 2029

(7 years from now)

US10548943 LA JOLLA PHARMA Method of treating low blood pressure Dec, 2029

(7 years from now)

US10500247 LA JOLLA PHARMA Method of treating low blood pressure Dec, 2029

(7 years from now)

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

Treatment: Treating refractory hypotension with about 5 ng/kg/min to about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor; Treating hypotension with about 20 ng/kg/min to about 40 ng/kg/min angiotensin ii in a human subject having septic shock; Increasing blood pressure with a rate of about 20 ng/kg/min to about 40 ng/kg/min angiotensin ii in a human subject having septic shock; increasing blood pressure with an initial rate of about 20 ng/kg/min angiotensin ii in a human subject having septic shock, and titrating the rate up.; Treating low blood pressure with angiotensin ii with an initial rate of about 5 ng/kg/min to about 20 ng/kg/min in a subject having refractory hypotension or severe hypotension, and titrating the rate up; treating low blood pressure with angiotensin ii with an initial rate of about 5 ng/kg/min to about 20 ng/kg/min in a subject having refractory hypotension or severe hypotension

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML) SOLUTION;INTRAVENOUS Discontinued

57. Drug name - GILOTRIF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8426586 BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Oct, 2029

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545884 BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992 Dec, 2029

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription

58. Drug name - GIMOTI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020361 EVOKE PHARMA INC Nasal formulations of metoclopramide Dec, 2029

(7 years from now)

Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient

Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 15MG BASE/SPRAY SPRAY, METERED;NASAL Prescription

59. Drug name - GIVLAARI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(7 years from now)

Drugs and Companies using GIVOSIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 189MG BASE/ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

60. Drug name - GLYXAMBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate Oct, 2029

(7 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG;5MG TABLET;ORAL Prescription
25MG;5MG TABLET;ORAL Prescription

61. Drug name - HARVONI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(6 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus Mar, 2029

(6 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2029

(6 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Sep, 2029

(6 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus Sep, 2029

(6 years from now)

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

More Information on Dosage
Strength Dosage Availability
33.75MG;150MG/PACKET PELLETS;ORAL Prescription
45MG;200MG/PACKET PELLETS;ORAL Prescription

62. Drug name - HORIZANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8795725 ARBOR PHARMS LLC GABA analog prodrug sustained release oral dosage forms Jun, 2029

(6 years from now)

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

Treatment: Treatment of moderate-to-severe primary restless leg syndrome in adults; management of postherpetic neuralgia (phn) in adults

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET, EXTENDED RELEASE;ORAL Prescription
600MG TABLET, EXTENDED RELEASE;ORAL Prescription

63. Drug name - IBSRELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8541448 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Dec, 2029

(7 years from now)

US8969377 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Dec, 2029

(7 years from now)

CN103819403A ARDELYX INC Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

CN103819403B ARDELYX INC Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

IN329133B ARDELYX INC Compounds And Methods For Inhibiting Nhemediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

IN201105002P4 ARDELYX INC Compounds And Methods For Inhibiting Sodium Hydrogen Exchanger-Mediated Antiport In Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

EP2384318A2 ARDELYX INC Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

EP3351248A1 ARDELYX INC Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

EP3351248B1 ARDELYX INC Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

EP2384318B1 ARDELYX INC Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders
Dec, 2029

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9408840 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder Dec, 2029

(7 years from now)

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET;ORAL Prescription

64. Drug name - INBRIJA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43711 ACORDA Pulmonary delivery for levodopa Feb, 2029

(6 years from now)

Drugs and Companies using LEVODOPA ingredient

Treatment: Intermittent treatment of off episodes in patients with parkinson's disease treated with carbidopa/levodopa by inhalation of levodopa powder particles

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
42MG POWDER;INHALATION Prescription

65. Drug name - INCRUSE ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8201556 GLAXO GRP ENGLAND Medicament dispenser Feb, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 62.5MCG BASE/INH POWDER;INHALATION Prescription

66. Drug name - INGREZZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8039627 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
Oct, 2029

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE CAPSULE;ORAL Prescription
EQ 60MG BASE CAPSULE;ORAL Prescription
EQ 80MG BASE CAPSULE;ORAL Prescription

67. Drug name - INOMAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431163 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas Jun, 2029

(6 years from now)

US8282966 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide Jun, 2029

(6 years from now)

US8795741 MALLINCKRODT HOSP Methods for treating patients who are candidates for inhaled nitric oxide treatment Jun, 2029

(6 years from now)

US8846112 MALLINCKRODT HOSP Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation Jun, 2029

(6 years from now)

US8293284 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide Jun, 2029

(6 years from now)

US8846112

(Pediatric)

MALLINCKRODT HOSP Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation Dec, 2029

(7 years from now)

US8282966

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide Dec, 2029

(7 years from now)

US8795741

(Pediatric)

MALLINCKRODT HOSP Methods for treating patients who are candidates for inhaled nitric oxide treatment Dec, 2029

(7 years from now)

US8431163

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas Dec, 2029

(7 years from now)

US8293284

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide Dec, 2029

(7 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: A method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide

Dosage: GAS;INHALATION

More Information on Dosage
Strength Dosage Availability
100PPM GAS;INHALATION Discontinued
800PPM GAS;INHALATION Prescription

68. Drug name - INTERMEZZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8242131 PURDUE PHARMA Methods of treating middle-of-the-night insomnia Aug, 2029

(6 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Treatment: Method of treating middle-of-the-night insomnia

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
1.75MG TABLET;SUBLINGUAL Discontinued
3.5MG TABLET;SUBLINGUAL Discontinued

69. Drug name - INVOKAMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
50MG;500MG TABLET;ORAL Prescription
50MG;1GM TABLET;ORAL Prescription
150MG;500MG TABLET;ORAL Prescription
150MG;1GM TABLET;ORAL Prescription

70. Drug name - INVOKAMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
50MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
50MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription
150MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
150MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription

71. Drug name - INVOKANA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
300MG TABLET;ORAL Prescription

72. Drug name - ISENTRESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7754731 MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7754731

(Pediatric)

MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor Sep, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 400MG BASE TABLET;ORAL Prescription
EQ 600MG BASE TABLET;ORAL Prescription

73. Drug name - ISTURISA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8314097 RECORDATI RARE Organic compounds
Mar, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE TABLET;ORAL Prescription
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription

74. Drug name - IZBA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144561 NOVARTIS Pharmaceutical compositions having desirable bioavailability Mar, 2029

(6 years from now)

US8754123 NOVARTIS Pharmaceutical compositions having desirable bioavailability May, 2029

(6 years from now)

US8722735 NOVARTIS Pharmaceutical compositions having desirable bioavailability Oct, 2029

(7 years from now)

US8178582 NOVARTIS Pharmaceutical compositions having desirable bioavailability Oct, 2029

(7 years from now)

Drugs and Companies using TRAVOPROST ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.003% SOLUTION/DROPS;OPHTHALMIC Discontinued

75. Drug name - JANUMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8414921

(Pediatric)

MERCK SHARP DOHME Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin Jan, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 50MG BASE TABLET;ORAL Prescription
500MG;EQ 50MG BASE TABLET;ORAL Prescription

76. Drug name - JARDIANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate Oct, 2029

(7 years from now)

Drugs and Companies using EMPAGLIFLOZIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
25MG TABLET;ORAL Prescription

77. Drug name - JATENZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8241664 CLARUS Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same Mar, 2029

(6 years from now)

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Treatment: Method of treating testosterone deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
158MG CAPSULE;ORAL Prescription
198MG CAPSULE;ORAL Prescription
237MG CAPSULE;ORAL Prescription

78. Drug name - JENTADUETO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Apr, 2029

(6 years from now)

US10973827 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Apr, 2029

(6 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Apr, 2029

(6 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET;ORAL Prescription
2.5MG;500MG TABLET;ORAL Prescription
2.5MG;850MG TABLET;ORAL Prescription

79. Drug name - JENTADUETO XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Apr, 2029

(6 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Apr, 2029

(6 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription

80. Drug name - JULUCA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(7 years from now)

CN102245182B VIIV HLTHCARE Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediates For Synthesis
Dec, 2029

(7 years from now)

CN102245182A VIIV HLTHCARE Synthesis Of Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediate
Dec, 2029

(7 years from now)

IN373756B VIIV HLTHCARE Process For The Preparation Of Carbamoylpyrid One Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

IN201838011858A VIIV HLTHCARE Process For The Preparation Of Carbamoylpyridone Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

EP2376080A4 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080B1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080A1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE;EQ 25MG BASE TABLET;ORAL Prescription

81. Drug name - KALYDECO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646481 VERTEX PHARMS Pharmaceutical composition and administrations thereof Aug, 2029

(6 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

82. Drug name - KALYDECO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646481 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof Aug, 2029

(6 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: NA

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG/PACKET GRANULE;ORAL Prescription
50MG/PACKET GRANULE;ORAL Prescription
75MG/PACKET GRANULE;ORAL Prescription

83. Drug name - KARBINAL ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667 AYTU Modified release formulations containing drug-ion exchange resin complexes Mar, 2029

(6 years from now)

Drugs and Companies using CARBINOXAMINE MALEATE ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
4MG/5ML SUSPENSION, EXTENDED RELEASE;ORAL Prescription

84. Drug name - KAZANO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8900638 TAKEDA PHARMS USA Solid preparation comprising alogliptin and metformin hydrochloride May, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE;1GM TABLET;ORAL Prescription
EQ 12.5MG BASE;500MG TABLET;ORAL Prescription

85. Drug name - KENGREAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925265 CHIESI Methods of treating or preventing stent thrombosis May, 2029

(6 years from now)

Drugs and Companies using CANGRELOR ingredient

Treatment: Method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous infusion

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/VIAL POWDER;INTRAVENOUS Prescription

86. Drug name - KERENDIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8436180 BAYER HLTHCARE Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
Apr, 2029

(6 years from now)

Drugs and Companies using FINERENONE ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

87. Drug name - KIMYRSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin Aug, 2029

(6 years from now)

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 1.2GM BASE/VIAL POWDER;INTRAVENOUS Prescription

88. Drug name - KISQALI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415355 NOVARTIS Pyrrolopyrimidine compounds and their uses
Aug, 2029

(6 years from now)

CN102186856B NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

CN102186856A NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

EP2331547B1 NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

EP2331547A1 NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136 NOVARTIS Pyrrolopyrimidine compounds and their uses Aug, 2029

(6 years from now)

US8962630 NOVARTIS Pyrrolopyrimidine compounds and their uses Dec, 2029

(7 years from now)

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

Treatment: In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; in combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

89. Drug name - KISQALI FEMARA CO-PACK (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415355 NOVARTIS Pyrrolopyrimidine compounds and their uses
Aug, 2029

(6 years from now)

CN102186856B NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

CN102186856A NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

EP2331547B1 NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

EP2331547A1 NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136 NOVARTIS Pyrrolopyrimidine compounds and their uses Aug, 2029

(6 years from now)

US8962630 NOVARTIS Pyrrolopyrimidine compounds and their uses Dec, 2029

(7 years from now)

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;EQ 200MG BASE TABLET;ORAL Prescription

90. Drug name - KLISYRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851470 ALMIRALL Composition and methods for modulating a kinase cascade
Feb, 2029

(6 years from now)

Drugs and Companies using TIRBANIBULIN ingredient

Treatment: NA

Dosage: OINTMENT;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% OINTMENT;TOPICAL Prescription

91. Drug name - KYLEENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561524 BAYER HLTHCARE Inserter Sep, 2029

(6 years from now)

US9615965 BAYER HLTHCARE Inserter Sep, 2029

(6 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: A method of positioning an intrauterine system (ius) by determining a depth of the uterus, holding an inserter handle with one hand, inserting the ius into the uterus, and retracting a slider on the handle to release the ius into the uterus; A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to release the intrauterine system

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage
Strength Dosage Availability
19.5MG INTRAUTERINE DEVICE;INTRAUTERINE Prescription

92. Drug name - KYNMOBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10821074 SUNOVION PHARMS INC Sublingual and buccal film compositions Aug, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
10MG FILM;SUBLINGUAL Prescription
15MG FILM;SUBLINGUAL Prescription
20MG FILM;SUBLINGUAL Prescription
25MG FILM;SUBLINGUAL Prescription
30MG FILM;SUBLINGUAL Prescription

93. Drug name - KYPROLIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511109 ONYX THERAP Combination therapy with peptide epoxyketones Oct, 2029

(7 years from now)

Drugs and Companies using CARFILZOMIB ingredient

Treatment: Kyprolis is indicated in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
10MG/VIAL POWDER;INTRAVENOUS Prescription
30MG/VIAL POWDER;INTRAVENOUS Prescription
60MG/VIAL POWDER;INTRAVENOUS Prescription

94. Drug name - LAMICTAL ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7919115 GLAXOSMITHKLINE LLC Orally disintegrating tablet compositions of lamotrigine
Jan, 2029

(6 years from now)

Drugs and Companies using LAMOTRIGINE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
50MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
100MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
200MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription

95. Drug name - LEQVIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8106022 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(7 years from now)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

96. Drug name - LO LOESTRIN FE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7704984 APIL Extended estrogen dosing contraceptive regimen Feb, 2029

(6 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient

Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.01MG,0.01MG;1MG,N/A TABLET;ORAL Prescription

97. Drug name - LO MINASTRIN FE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7704984 APIL Extended estrogen dosing contraceptive regimen Feb, 2029

(6 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient

Treatment: Prevention of pregnancy

Dosage: TABLET, CHEWABLE, TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.01MG,0.01MG,N/A;1MG,N/A,N/A TABLET, CHEWABLE, TABLET;ORAL Discontinued

98. Drug name - LONHALA MAGNAIR KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940110 SUNOVION RESP Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations Feb, 2029

(6 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION;INHALATION

More Information on Dosage
Strength Dosage Availability
25MCG/ML SOLUTION;INHALATION Prescription

99. Drug name - LONSURF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46284 TAIHO ONCOLOGY Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor Sep, 2029

(6 years from now)

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

Treatment: Treatment of adults with metastatic gastric or gja previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropiate, her2/neu-targeted therapy; treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 6.14MG BASE;15MG TABLET;ORAL Prescription
EQ 8.19MG BASE;20MG TABLET;ORAL Prescription

100. Drug name - LYNPARZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8475842 ASTRAZENECA Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Dec, 2029

(7 years from now)

Drugs and Companies using OLAPARIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
150MG TABLET;ORAL Prescription

101. Drug name - MILPROSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537584 FERRING PHARMS INC Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof Feb, 2029

(6 years from now)

US10548904 FERRING PHARMS INC Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof Feb, 2029

(6 years from now)

Drugs and Companies using PROGESTERONE ingredient

Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women

Dosage: SYSTEM;VAGINAL

More Information on Dosage
Strength Dosage Availability
1.78GM SYSTEM;VAGINAL Discontinued

102. Drug name - MIRAPEX ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679533 BOEHRINGER INGELHEIM Pramipexole once-daily dosage form Sep, 2029

(6 years from now)

Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient

Treatment: Treatment of parkinson's disease

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
0.375MG TABLET, EXTENDED RELEASE;ORAL Prescription
0.75MG TABLET, EXTENDED RELEASE;ORAL Prescription
1.5MG TABLET, EXTENDED RELEASE;ORAL Prescription
2.25MG TABLET, EXTENDED RELEASE;ORAL Prescription
3MG TABLET, EXTENDED RELEASE;ORAL Prescription
3.75MG TABLET, EXTENDED RELEASE;ORAL Prescription
4.5MG TABLET, EXTENDED RELEASE;ORAL Prescription

103. Drug name - MIRENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9615965 BAYER HLTHCARE Inserter Sep, 2029

(6 years from now)

US10561524 BAYER HLTHCARE Inserter Sep, 2029

(6 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to release the intrauterine system; A method of positioning an intrauterine system (ius) by determining a depth of the uterus, holding an inserter handle with one hand, inserting the ius into the uterus, and retracting a slider on the handle to release the ius into the uterus

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage
Strength Dosage Availability
52MG INTRAUTERINE DEVICE;INTRAUTERINE Prescription

104. Drug name - MITOSOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7806265 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application Feb, 2029

(6 years from now)

US9649428 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application May, 2029

(6 years from now)

Drugs and Companies using MITOMYCIN ingredient

Treatment: Mitosol is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. it is intended for topical application to the site of glaucoma filtration surgery

Dosage: FOR SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.2MG/VIAL FOR SOLUTION;TOPICAL Prescription

105. Drug name - MONOFERRIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10414831 PHARMACOSMOS AS Stable iron oligosaccharide compound
Mar, 2029

(6 years from now)

US8815301 PHARMACOSMOS AS Stable iron oligosaccharide compound
Aug, 2029

(6 years from now)

IN291100B PHARMACOSMOS AS A Stable Iron Oligosaccharide Compound
Mar, 2029

(6 years from now)

IN201108145P1 PHARMACOSMOS AS A Stable Iron Oligosaccharide Compound
Mar, 2029

(6 years from now)

EP2411053B1 PHARMACOSMOS AS A Stable Iron Oligosaccharide Compound
Mar, 2029

(6 years from now)

EP3156075A1 PHARMACOSMOS AS An Oligosaccharide And A Process For Preparation Thereof
Mar, 2029

(6 years from now)

EP3156075B1 PHARMACOSMOS AS An Oligosaccharide And A Process For Preparation Thereof
Mar, 2029

(6 years from now)

EP2411053A1 PHARMACOSMOS AS A Stable Iron Oligosaccharide Compound
Mar, 2029

(6 years from now)

Drugs and Companies using FERRIC DERISOMALTOSE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM/10ML (100MG/ML) SOLUTION;INTRAVENOUS Prescription
100MG/ML (100MG/ML) SOLUTION;INTRAVENOUS Discontinued
500MG/5ML (100MG/ML) SOLUTION;INTRAVENOUS Discontinued

106. Drug name - MOXEZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450311 NOVARTIS Pharmaceutical compositions containing a fluoroquinolone antibiotic drug May, 2029

(6 years from now)

US9114168 NOVARTIS Pharmaceutical compositions containing a fluoroquinolone antibiotic drug May, 2029

(6 years from now)

Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.5% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

107. Drug name - MULTAQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410167 SANOFI AVENTIS US Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality Apr, 2029

(6 years from now)

US9107900 SANOFI AVENTIS US Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality Apr, 2029

(6 years from now)

Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient

Treatment: Reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; Reduction in risk of hospitalization in patients with stable nyha class iii heart failure and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 400MG BASE TABLET;ORAL Prescription

108. Drug name - MYCAPSSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8329198 AMRYT Pharmaceutical compositions and related methods of delivery Sep, 2029

(6 years from now)

US8535695 AMRYT Pharmaceutical compositions and related methods of delivery Sep, 2029

(6 years from now)

US9265812 AMRYT Pharmaceutical compositions and related methods of delivery Sep, 2029

(6 years from now)

US9566246 AMRYT Pharmaceutical compositions and related methods of delivery Sep, 2029

(6 years from now)

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE CAPSULE, DELAYED RELEASE;ORAL Prescription

109. Drug name - MYDAYIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846100 TAKEDA PHARMS USA Controlled dose drug delivery system Aug, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
3.125MG;3.125MG;3.125MG;3.125MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
6.25MG;6.25MG;6.25MG;6.25MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
9.375MG;9.375MG;9.375MG;9.375MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
12.5MG;12.5MG;12.5MG;12.5MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

110. Drug name - MYRBETRIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8772315

(Pediatric)

APGDI Pharmaceutical composition for treating overactive bladder Apr, 2029

(6 years from now)

US10842780 APGDI Pharmaceutical composition for modified release Sep, 2029

(6 years from now)

Drugs and Companies using MIRABEGRON ingredient

Treatment: Administration of an extended release tablet for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET, EXTENDED RELEASE;ORAL Prescription
50MG TABLET, EXTENDED RELEASE;ORAL Prescription

111. Drug name - NAMENDA XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8039009 ALLERGAN Modified release formulations of memantine oral dosage forms Mar, 2029

(6 years from now)

US8039009

(Pediatric)

ALLERGAN Modified release formulations of memantine oral dosage forms Sep, 2029

(6 years from now)

Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient

Treatment: Treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
7MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
14MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
21MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
28MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

112. Drug name - NAMZARIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8039009 ALLERGAN Modified release formulations of memantine oral dosage forms Mar, 2029

(6 years from now)

US8039009

(Pediatric)

ALLERGAN Modified release formulations of memantine oral dosage forms Sep, 2029

(6 years from now)

US8058291 ALLERGAN Methods and compositions for the treatment of CNS-related conditions Dec, 2029

(7 years from now)

Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient

Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG;7MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;14MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;21MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;28MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

113. Drug name - NERLYNX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265784 PUMA BIOTECH Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine Aug, 2029

(6 years from now)

Drugs and Companies using NERATINIB MALEATE ingredient

Treatment: Use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE TABLET;ORAL Prescription

114. Drug name - NESINA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8697125 TAKEDA PHARMS USA Tablet preparation without causing a tableting trouble Jun, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 6.25MG BASE TABLET;ORAL Prescription
EQ 12.5MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription

115. Drug name - NEURACEQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7807135 LIFE MOLECULAR Stilbene derivatives and their use for binding and imaging amyloid plaques
Mar, 2029

(6 years from now)

EP2213652B1 LIFE MOLECULAR Stilbene Derivatives And Their Use For Binding And Imaging Amyloid Plaques
Feb, 2029

(6 years from now)

EP2213652A1 LIFE MOLECULAR Stilbene Derivatives And Their Use For Binding And Imaging Amyloid Plaques
Feb, 2029

(6 years from now)

Drugs and Companies using FLORBETABEN F-18 ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
30ML (1.4-135mCi/ML) SOLUTION;INTRAVENOUS Prescription

116. Drug name - NEXTERONE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7635773 BAXTER HLTHCARE Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

Drugs and Companies using AMIODARONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage
Strength Dosage Availability
50MG/ML INJECTABLE;INJECTION Discontinued
150MG/100ML (1.5MG/ML) INJECTABLE;INJECTION Prescription
360MG/200ML (1.8MG/ML) INJECTABLE;INJECTION Prescription

117. Drug name - NICORETTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940772 GLAXOSMITHKLINE Nicotine lozenge composition Apr, 2029

(6 years from now)

US8501164 GLAXOSMITHKLINE Nicotine lozenge compositions Jun, 2029

(6 years from now)

Drugs and Companies using NICOTINE POLACRILEX ingredient

Treatment: NA

Dosage: TROCHE/LOZENGE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2MG BASE TROCHE/LOZENGE;ORAL Over the counter
EQ 4MG BASE TROCHE/LOZENGE;ORAL Over the counter

118. Drug name - NINLARO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8859504 TAKEDA PHARMS USA Boronate ester compounds and pharmaceutical compositions thereof
Jun, 2029

(6 years from now)

US7442830 TAKEDA PHARMS USA Proteasome inhibitors
Nov, 2029

(7 years from now)

IN290327B TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jun, 2029

(6 years from now)

IN201100107P1 TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jun, 2029

(6 years from now)

EP2318419B1 TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jun, 2029

(6 years from now)

EP2318419A1 TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jun, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9175017 TAKEDA PHARMS USA Boronate ester compounds and pharmaceutical compositions thereof Jun, 2029

(6 years from now)

Drugs and Companies using IXAZOMIB CITRATE ingredient

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.3MG BASE CAPSULE;ORAL Prescription
EQ 3MG BASE CAPSULE;ORAL Prescription
EQ 4MG BASE CAPSULE;ORAL Prescription

119. Drug name - NITROLINGUAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7872049 POHL BOSKAMP Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate Mar, 2029

(6 years from now)

Drugs and Companies using NITROGLYCERIN ingredient

Treatment: Method of treating angina pectoris

Dosage: SPRAY, METERED;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
0.4MG/SPRAY SPRAY, METERED;SUBLINGUAL Prescription

120. Drug name - NOCDURNA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020448 FERRING PHARMS INC Methods comprising desmopressin May, 2029

(6 years from now)

US10137167 FERRING PHARMS INC Methods comprising desmopressin May, 2029

(6 years from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Treatment: Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
0.0277MG TABLET;SUBLINGUAL Prescription
0.0553MG TABLET;SUBLINGUAL Prescription

121. Drug name - NOXAFIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117951 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US8410077 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US9750822 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

Drugs and Companies using POSACONAZOLE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
300MG/16.7ML (18MG/ML) SOLUTION;INTRAVENOUS Prescription

122. Drug name - NUZYRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265740 PARATEK PHARMS INC Minocycline compounds and methods of use thereof Mar, 2029

(6 years from now)

US10124014 PARATEK PHARMS INC Minocycline compounds and methods of use thereof Mar, 2029

(6 years from now)

US9724358 PARATEK PHARMS INC Minocycline compounds and methods of use thereof Mar, 2029

(6 years from now)

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

Treatment: Treatment of bacterial skin and skin structure infection; Treatment of bacterial skin and skin structure infections

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE TABLET;ORAL Prescription

123. Drug name - ODOMZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178563 SUN PHARM Compounds and compositions as hedgehog pathway modulators
Jul, 2029

(6 years from now)

US8063043 SUN PHARM Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide
Sep, 2029

(6 years from now)

CN102159570B SUN PHARM Salts Of N-[6-Cis-2,6-Dimethylmorpholin-4Yl)Pyridine-3Yl]-2-Methyl-4'-(Trifluoromethoxy)[1,1'-Biphenyl]-3-Carboxamide
Sep, 2029

(6 years from now)

CN102159570A SUN PHARM Salts Of N-[6-Cis-2,6-Dimethylmorpholin-4Yl)Pyridine-3Yl]-2-Methyl-4'-(Trifluoromethoxy)[1,1'-Biphenyl]-3-Carboxamide
Sep, 2029

(6 years from now)

EP2342198B1 SUN PHARM A Diphosphate Salt Of N-[6-Cis-2,6-Dimethylmorpholin-4Yl)Pyridine-3Yl]-2-Methyl-4'-(Trifluoromethoxy)[1,1'-Biphenyl]-3-Carboxamide
Sep, 2029

(6 years from now)

EP2342198A1 SUN PHARM A Diphosphate Salt Of N-[6-Cis-2,6-Dimethylmorpholin-4Yl)Pyridine-3Yl]-2-Methyl-4'-(Trifluoromethoxy)[1,1'-Biphenyl]-3-Carboxamide
Sep, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE CAPSULE;ORAL Prescription

124. Drug name - OFEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10105323 BOEHRINGER INGELHEIM Pharmaceutical dosage form for immediate release of an indolinone derivative Jun, 2029

(6 years from now)

US9907756 BOEHRINGER INGELHEIM Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative Jun, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription

125. Drug name - OFIRMEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987238

(Pediatric)

MALLINCKRODT HOSP Reduced dose intravenous acetaminophen May, 2029

(6 years from now)

US9610265

(Pediatric)

MALLINCKRODT HOSP Reduced dose intravenous acetaminophen May, 2029

(6 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM/100ML (10MG/ML) SOLUTION;INTRAVENOUS Discontinued

126. Drug name - OLEPTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8133893 ANGELINI PHARMA Trazodone and trazodone hydrochloride in purified form
Mar, 2029

(6 years from now)

Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET, EXTENDED RELEASE;ORAL Discontinued
300MG TABLET, EXTENDED RELEASE;ORAL Discontinued

127. Drug name - OLUMIANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420629 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors Mar, 2029

(6 years from now)

Drugs and Companies using BARICITINIB ingredient

Treatment: Treatment of rheumatoid arthritis

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription

128. Drug name - OLYSIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148399 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Sep, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE CAPSULE;ORAL Discontinued

129. Drug name - ONGENTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8168793 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
Apr, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524746 NEUROCRINE Dosage regimen for COMT inhibitors Jul, 2029

(6 years from now)

Drugs and Companies using OPICAPONE ingredient

Treatment: Method of treating parkinson's disease

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE;ORAL Prescription
50MG CAPSULE;ORAL Prescription

130. Drug name - ONPATTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8168775 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(7 years from now)

US10240152 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(7 years from now)

CN102186978B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN103937793B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN106834291A ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN106834291B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN102186978A ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN103937793A ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

IN307782B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

IN201103301P4 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP2344639A2 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP3354733A1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP2344639B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP3354733B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP2937418A1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP2937418B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492359 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US8822668 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US9364435 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US11141378 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US8058069 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US8741866 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin Oct, 2029

(7 years from now)

US9234196 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin Oct, 2029

(7 years from now)

Drugs and Companies using PATISIRAN SODIUM ingredient

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/5ML (EQ 2MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

131. Drug name - ONZETRA XSAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076615 CURRAX Nasal delivery Jul, 2029

(6 years from now)

US8550073 CURRAX Nasal delivery Oct, 2029

(7 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; method of delivering sumatriptan to a nasal cavity

Dosage: POWDER;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 11MG BASE POWDER;NASAL Prescription

132. Drug name - OPANA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851482 ENDO PHARMS Method for making analgesics
Jul, 2029

(6 years from now)

US8871779 ENDO PHARMS Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds
Nov, 2029

(7 years from now)

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET, EXTENDED RELEASE;ORAL Discontinued
7.5MG TABLET, EXTENDED RELEASE;ORAL Discontinued
10MG TABLET, EXTENDED RELEASE;ORAL Discontinued
15MG TABLET, EXTENDED RELEASE;ORAL Discontinued
20MG TABLET, EXTENDED RELEASE;ORAL Discontinued
30MG TABLET, EXTENDED RELEASE;ORAL Discontinued
40MG TABLET, EXTENDED RELEASE;ORAL Discontinued

133. Drug name - OPSUMIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268847 ACTELION Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor Apr, 2029

(6 years from now)

Drugs and Companies using MACITENTAN ingredient

Treatment: Method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription

134. Drug name - ORBACTIV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin Aug, 2029

(6 years from now)

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

Treatment: Treatment of bacterial skin and skin structure infections using a single dose

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 400MG BASE/VIAL POWDER;INTRAVENOUS Prescription

135. Drug name - ORKAMBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646481 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof Aug, 2029

(6 years from now)

US9192606 VERTEX PHARMS INC Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid Sep, 2029

(6 years from now)

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

Treatment: Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using a dosage unit as defined in claim 1 of u.s. patent no. 9,192,606

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
125MG/PACKET;100MG/PACKET GRANULE;ORAL Prescription
188MG/PACKET;150MG/PACKET GRANULE;ORAL Prescription

136. Drug name - OSENI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8637079 TAKEDA PHARMS USA Solid preparation comprising alogliptin and pioglitazone Jun, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE;EQ 15MG BASE TABLET;ORAL Prescription
EQ 12.5MG BASE;EQ 30MG BASE TABLET;ORAL Prescription
EQ 12.5MG BASE;EQ 45MG BASE TABLET;ORAL Prescription
EQ 25MG BASE;EQ 15MG BASE TABLET;ORAL Prescription
EQ 25MG BASE;EQ 30MG BASE TABLET;ORAL Prescription
EQ 25MG BASE;EQ 45MG BASE TABLET;ORAL Prescription

137. Drug name - OTIPRIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9603796 ALK ABELLO Controlled release antimicrobial compositions and methods for the treatment of otic disorders
Apr, 2029

(6 years from now)

CN102026623A ALK ABELLO Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders
May, 2029

(6 years from now)

CN102026623B ALK ABELLO Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders
May, 2029

(6 years from now)

CN104352429B ALK ABELLO For Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders
Jul, 2029

(6 years from now)

CN104352429A ALK ABELLO Controlled Release Antimicrobial Composition And Method For Treating Ear Part Condition
Jul, 2029

(6 years from now)

EP2303227A4 ALK ABELLO Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders
May, 2029

(6 years from now)

EP2303227A2 ALK ABELLO Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders
May, 2029

(6 years from now)

EP2303227B1 ALK ABELLO Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders
May, 2029

(6 years from now)

EP2299979A4 ALK ABELLO Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders
Jul, 2029

(6 years from now)

EP2299979B1 ALK ABELLO Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders
Jul, 2029

(6 years from now)

EP2299979A2 ALK ABELLO Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders
Jul, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9205048 ALK ABELLO Controlled release antimicrobial compositions and methods for the treatment of otic disorders Apr, 2029

(6 years from now)

US9233068 ALK ABELLO Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders Dec, 2029

(7 years from now)

Drugs and Companies using CIPROFLOXACIN ingredient

Treatment: Treatment of pediatric patients with otitis media with effusion undergoing tympanostomy tube placement

Dosage: INJECTABLE, SUSPENSION;OTIC

More Information on Dosage
Strength Dosage Availability
6% (60MG/ML) INJECTABLE, SUSPENSION;OTIC Prescription

138. Drug name - OTREXUP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10709844 OTTER PHARMS Injector safety device Mar, 2029

(6 years from now)

US9867949 OTTER PHARMS Injector safety device Mar, 2029

(6 years from now)

Drugs and Companies using METHOTREXATE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
7.5MG/0.4ML (7.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Discontinued
10MG/0.4ML (10MG/0.4ML) SOLUTION;SUBCUTANEOUS Discontinued
12.5MG/0.4ML (12.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
15MG/0.4ML (15MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
17.5MG/0.4ML (17.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
20MG/0.4ML (20MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
22.5MG/0.4ML (22.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
25MG/0.4ML (25MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
15MG/0.6ML (15MG/0.6ML) SOLUTION;SUBCUTANEOUS Discontinued
17.5MG/0.7ML (17.5MG/0.7ML) SOLUTION;SUBCUTANEOUS Discontinued
20MG/0.8ML (20MG/0.8ML) SOLUTION;SUBCUTANEOUS Discontinued
22.5MG/0.9ML (22.5MG/0.9ML) SOLUTION;SUBCUTANEOUS Discontinued
25MG/ML (25MG/ML) SOLUTION;SUBCUTANEOUS Discontinued

139. Drug name - OXLUMO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(7 years from now)

Drugs and Companies using LUMASIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE) SOLUTION;SUBCUTANEOUS Prescription

140. Drug name - PENNSAID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741956 HORIZON Treatment of pain with topical diclofenac Jul, 2029

(6 years from now)

US8618164 HORIZON Treatment of pain with topical diclofenac compounds Jul, 2029

(6 years from now)

US9370501 HORIZON Treatment of pain with topical diclofenac Jul, 2029

(6 years from now)

US8217078 HORIZON Treatment of pain with topical diclofenac Jul, 2029

(6 years from now)

US9375412 HORIZON Treatment of pain with topical diclofenac Jul, 2029

(6 years from now)

US9415029 HORIZON Treatment of pain with topical diclofenac Jul, 2029

(6 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Treatment: Combination use of topical diclofenac on the knee and administration of an oral nsaid.; Use of topical diclofenac on the knee and a second topical prescription medication on the same knee; Use of topical diclofenac sodium for treating pain

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
2% SOLUTION;TOPICAL Prescription

141. Drug name - PENNSAID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8217078 NUVO PHARMS INC Treatment of pain with topical diclofenac Jul, 2029

(6 years from now)

US8618164 NUVO PHARMS INC Treatment of pain with topical diclofenac compounds Jul, 2029

(6 years from now)

US8741956 NUVO PHARMS INC Treatment of pain with topical diclofenac Jul, 2029

(6 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Treatment: Use of topical diclofenac on the knee and a second topical medication on the same knee; Use of topical diclofenac on the knee and a second topical prescription medication on the same knee; Combination use of topical diclofenac on the knee and administration of an oral nsaid.

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
1.5% SOLUTION;TOPICAL Discontinued

142. Drug name - PIQRAY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476268 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2029

(6 years from now)

CN102149711B NOVARTIS Organic Compounds
Sep, 2029

(6 years from now)

CN102149711A NOVARTIS Organic Compounds
Sep, 2029

(6 years from now)

IN307469B NOVARTIS The Compound (S)-Pyrrolidine-1,2-Dicarboxylic Acid 2-Amide-1- ({4-Methyl-5-[2-(2,2,2-Trifluoro-1,1-Dimethyl-Ethyl)- Pyridin-4-Yl]-Thiazol-2-Yl}-Amide)
Sep, 2029

(6 years from now)

EP2331537A1 NOVARTIS 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases
Sep, 2029

(6 years from now)

EP2331537B1 NOVARTIS 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases
Sep, 2029

(6 years from now)

Drugs and Companies using ALPELISIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
150MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription

143. Drug name - PRESTALIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7846961 ADHERA α crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it
Oct, 2029

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE;3.5MG TABLET;ORAL Prescription
EQ 5MG BASE;7MG TABLET;ORAL Prescription
EQ 10MG BASE;14MG TABLET;ORAL Prescription

144. Drug name - PREZCOBIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148374 JANSSEN PRODS Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;800MG TABLET;ORAL Prescription

145. Drug name - PYLARIFY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9861713 PROGENICS PHARMS INC PSMA-binding agents and uses thereof
Jul, 2029

(6 years from now)

CN107382846B PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

CN102171187A PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

CN102171187B PROGENICS PHARMS INC Psma- Binding Agent And Use Thereof
Jul, 2029

(6 years from now)

CN107382846A PROGENICS PHARMS INC Psma- Binding Agent And Use Thereof
Jul, 2029

(6 years from now)

IN315927B PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

EP2318366B1 PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

EP3222615B1 PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

EP2318366A2 PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

EP2318366A4 PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

EP3222615A1 PROGENICS PHARMS INC Psma-Binding Agents And Uses Thereof
Jul, 2029

(6 years from now)

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50ML (1-80mCi/ML) SOLUTION;INTRAVENOUS Prescription

146. Drug name - QBREXZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618160 JOURNEY Topical glycopyrrolate formulations Dec, 2029

(7 years from now)

Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: CLOTH;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 2.4% BASE CLOTH;TOPICAL Prescription

147. Drug name - QSYMIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580298 VIVUS Low dose topiramate/phentermine composition and methods of use thereof May, 2029

(6 years from now)

US8580299 VIVUS Escalating dosing regimen for effecting weight loss and treating obesity Jun, 2029

(6 years from now)

Drugs and Companies using PHENTERMINE HYDROCHLORIDE; TOPIRAMATE ingredient

Treatment: Use of qsymia (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 3.75MG BASE;23MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 7.5MG BASE;46MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 11.25MG BASE;69MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 15MG BASE;92MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

148. Drug name - QTERN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(7 years from now)

More Information on Dosage
Strength Dosage Availability
5MG;EQ 5MG BASE TABLET;ORAL Prescription
10MG;EQ 5MG BASE TABLET;ORAL Prescription

149. Drug name - QTERNMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(7 years from now)

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

150. Drug name - QUARTETTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8415332 TEVA BRANDED PHARM Methods of hormonal treatment utilizing ascending-dose extended cycle regimens Mar, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A TABLET;ORAL Prescription

151. Drug name - QUILLIVANT XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667 NEXTWAVE Modified release formulations containing drug-ion exchange resin complexes Mar, 2029

(6 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/ML FOR SUSPENSION, EXTENDED RELEASE;ORAL Prescription

152. Drug name - RASUVO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8664231 MEDEXUS Concentrated methotrexate solutions Jun, 2029

(6 years from now)

Drugs and Companies using METHOTREXATE ingredient

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
7.5MG/0.15ML (7.5MG/0.15ML) SOLUTION;SUBCUTANEOUS Prescription
10MG/0.20ML (10MG/0.20ML) SOLUTION;SUBCUTANEOUS Prescription
12.5MG/0.25ML (12.5MG/0.25ML) SOLUTION;SUBCUTANEOUS Prescription
15MG/0.30ML (15MG/0.30ML) SOLUTION;SUBCUTANEOUS Prescription
17.5MG/0.35ML (17.5MG/0.35ML) SOLUTION;SUBCUTANEOUS Prescription
20MG/0.4ML (20MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
22.5MG/0.45ML (22.5MG/0.45ML) SOLUTION;SUBCUTANEOUS Prescription
25MG/0.5ML (25MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
27.5MG/0.55ML (27.5MG/0.55ML) SOLUTION;SUBCUTANEOUS Discontinued
30MG/0.6ML (30MG/0.6ML) SOLUTION;SUBCUTANEOUS Prescription

153. Drug name - RECARBRIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Nov, 2029

(7 years from now)

CN102827067B MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

CN101918407B MSD MERCK CO Beta-Lactam Enzyme Inhibitor
Jan, 2029

(6 years from now)

CN102827067A MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

CN101918407A MSD MERCK CO Beta-1Actamase Inhibitors
Jan, 2029

(6 years from now)

IN293446B MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

IN201003977P4 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

EP2666774A1 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

EP2666774B1 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

EP2231667B1 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

EP2231667A2 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL POWDER;INTRAVENOUS Prescription

154. Drug name - RELISTOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180125 SALIX Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US9492445 SALIX Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US8420663 SALIX Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US9724343 SALIX Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

155. Drug name - RELISTOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492445 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US8822490 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US9180125 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US8420663 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
8MG/0.4ML (8MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
12MG/0.6ML (12MG/0.6ML) SOLUTION;SUBCUTANEOUS Prescription

156. Drug name - REMODULIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).